Citation Tools
PDFEmerging technologies, pharmacology and therapeutics
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease